The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review

Almutairi, Khalid; Nossent, Jiri; Preen, David B.; Keen, Helen; Inderjeeth, Charles

doi:10.1007/s00296-020-04731-0

Cited by 457 publications

(301 citation statements)

References 69 publications

Supporting

Mentioning

285

Contrasting

Unclassified

Order By: Relevance

“…Asia Pacific is a vast, diverse region, with a sizeable burden of rheumatoid arthritis (RA), which affects the quality of life of patients and consumes healthcare resources 1‐3 The prevalence of RA in Asia Pacific (around 0.30%‐0.50%) compared with North America (0.70%) and Europe (0.59%) is relatively lower but, given the large populations, this translates to a huge burden in the region (Figure 1). 4‐8 …”

Section: Introductionmentioning

confidence: 99%

Rheumatoid arthritis management in the APLAR region: Perspectives from an expert panel of rheumatologists, patients and community oriented program for control of rheumatic diseases

Chopra¹,

Lin

Navarra

et al. 2021

Int J of Rheum Dis

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a major health burden in Asia Pacific affecting the quality of life of patients and consuming healthcare resources. According to recent estimates from the World Health Organization‐International League Against Rheumatism‐Community Oriented Program for Control of Rheumatic Diseases, prevalence is around 0.3%‐0.5%. Management guidelines have helped to improve treatment across this diverse region. To gain better insight into current real‐world management applications in view of these guidelines, virtual meetings were conducted in mid‐2020 to explore perspectives of rheumatologists and patients, as well as discuss the impact of coronavirus disease 2019 on RA management. Patients and rheumatologists from Hong Kong, Malaysia, Singapore, the Philippines, Thailand, India, Pakistan, and Taiwan were included, representing a diverse mix of healthcare systems, wealth, ethnicity and culture. Despite many countries having prospered in recent years, similar challenges in RA diagnosis and treatment were identified. The daily impact and patient experience of RA were also similar across countries, marked by “silent” pain and disability, and universal misunderstanding of the disease. Late diagnosis and treatment, and barriers to access to appropriate treatment, remain problematic. The experience shared by Taiwan offers a glimmer of hope, however, wherein patient advocacy groups have succeeded in being included in policy‐making decisions and securing access to advanced treatment. Real‐world solutions that pay heed to the unique local needs and diversity of Asia Pacific are required to improve RA management, which will take time. In the interim, help can be sought from the trained, non‐rheumatologist community to reduce some of the disease burden.

show abstract

Section: Introductionmentioning

confidence: 99%

Rheumatoid arthritis management in the APLAR region: Perspectives from an expert panel of rheumatologists, patients and community oriented program for control of rheumatic diseases

Chopra¹,

Lin

Navarra

et al. 2021

Int J of Rheum Dis

View full text Add to dashboard Cite

show abstract

“… 1 A heightened cardiovascular risk also exists which closely follows disease activity. 2 As the global prevalence of RA approximates 0.5%, 3 the disease poses a substantial healthcare burden on both the individual and society. Although RA remains incurable, the evolution of its management has led to unprecedented improvements in outcomes.…”

Section: Introductionmentioning

confidence: 99%

Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician

Findeisen¹,

Sewell²,

Östör³

2021

BTT

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a disease characterised by inflammation of synovial joints and poses a substantial healthcare burden on both the individual and society. One of the most significant shifts in the RA therapeutic landscape has occurred with the introduction of biological disease modifying anti-rheumatic drugs (bDMARDs). There are five classes of bDMARDs currently available, each with a different molecular target and subtle differences in their efficacy and safety profile. This review also describes the “real-world” use of bDMARDs and how they fit into the overall RA treatment guidelines.

show abstract

“…Rheumatoid arthritis (RA) is a common chronic autoimmune disease with high morbidity and mortality that primarily affects joints 1 . Joint pain is a cardinal clinical feature of RA that significantly impacts quality of life 2 .…”

Section: Introductionmentioning

confidence: 99%

miR-544-3p mediates arthritis pain through regulation of FcγRI

Liu

Jeon

2021

Preprint

View full text Add to dashboard Cite

Chronic or episodic joint pain is a major symptom in rheumatoid arthritis (RA) and its adequate treatment represents an unmet medical need. However, the cellular and molecular mechanisms underlying RA pain remain elusive. Non-coding microRNAs (miRNAs) have been implicated in the pathogenesis of RA as negative regulators of the stability or translation of specific target mRNAs. Yet, their significance in RA pain is still not well defined. We and other groups recently identified neuronally expressed FcγRI as a key driver of arthritis pain in mouse RA models. Thus, we tested the hypothesis that miRNAs that target and regulate neuronal FcγRI attenuate RA pain. Here, we show that miR-544-3p was robustly downregulated whereas FcγRI was significantly upregulated in the dorsal root ganglion (DRG) in mouse RA models. Intrathecal injection of miR-544-3p mimic attenuated established mechanical and heat hyperalgesia in a mouse model of collagen II-induced arthritis (CIA). Moreover, this effect was likely mediated, at least in part, by FcγRI since miR-544-3p mimic downregulated FcγRI in the DRG during arthritis and genetic deletion of FcγRI produced similar antihyperalgesic effects in the CIA model. This notion was further supported by a dual luciferase assay showing that miR-544-3p targeted FcγRI by directly binding to its 3’UTR. In addition, FcγRI expression in DRG neurons in vitro was downregulated by miR-544-3p mimic and upregulated by miR-544-3p inhibitor. In naïve mice, miR-544-3p mimic alleviated acute joint pain hypersensitivity induced by IgG immune complex (IgG-IC), whereas miR-544-3p inhibitor potentiated the pro-nociceptive behavioral effect of IgG-IC. These findings suggest that miR-544-3p causally participates in the maintenance of arthritis pain by targeting neuronal FcγRI, and thus define miR-544-3p as a new potential therapeutic target for treating RA pain.

show abstract

The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review

Cited by 457 publications

References 69 publications

Rheumatoid arthritis management in the APLAR region: Perspectives from an expert panel of rheumatologists, patients and community oriented program for control of rheumatic diseases

Rheumatoid arthritis management in the APLAR region: Perspectives from an expert panel of rheumatologists, patients and community oriented program for control of rheumatic diseases

Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician

miR-544-3p mediates arthritis pain through regulation of FcγRI

Contact Info

Product

Resources

About